Clinical Trials Browser

Recruiting × NIH × Inotuzumab Ozogamicin × Clear all

NCT03739814 2026-06-03

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Phase 2 Recruiting

Burkitt Lymphoma